Generated by AI
HUTCHMED (China) Limited ADR is an American depositary receipt representing shares of HUTCHMED (China) Limited, a biopharmaceutical company focused on discovering, developing, and commercializing targeted therapies and immunotherapies for cancer and immunological diseases. The company’s current portfolio spans oncology and immunology research, clinical development, regulatory activities, manufacturing, and commercialization, with products and candidates aimed at addressing unmet medical needs across multiple therapeutic areas. HUTCHMED also operates other commercial businesses, including the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. Based in Hong Kong, the company serves markets in China and internationally through a combination of in-house development and commercial infrastructure. As an ADR, HUTCHMED (China) Limited provides investors with access to the company’s underlying ordinary shares in a U.S.-traded format.
WebsiteCheung Kong Center
Hong Kong
Hong Kong
The latest articles about HCM.
HUTCHMED (China) reported that ORPATHYS (savolitinib) plus TAGRISSO (osimertinib) delivered statistically significant progression free and overall survival benefits in the Phase III SAFFRON and SANOVO lung cancer trials. Regulatory filings for the combination have been accepted in Europe and Japan, following prior submissions in the US and existing approvals in China and Switzerland. The same savolitinib and TAGRISSO combination now spans late stage global data, multiple commercial...
HUTCHMED (China) has seen its share price fall sharply in recent years, even as it continues to advance its drug pipeline, which raises a straightforward question for investors who follow HUTCHMED closely. Is the current valuation of the stock well aligned with what the business is earning today and what those earnings suggest about its long term potential? Over the past 5 years the share price has declined 54.8%, which puts the focus squarely on whether the current earnings base can support...
Summary of Jan 7's posts. Generated by AI.
No summary yet.
No summary yet.
Summary of Mar 19's posts. Generated by AI.
Summary of Aug 12's posts. Generated by AI.
Investors talking about HCM also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.